NCT03291379View on ClinicalTrials.gov

Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

August 3, 2019

Study Completion Date

August 3, 2019

Conditions
Carcinoma, HepatocellularMetastatic Colorectal Cancer
Interventions
DRUG

BTG-002814

BTG-002814 containing 100 mg vandetanib

Trial Locations (1)

NW1 2BU

University College London Hospital, Bloomsbury

Sponsors
All Listed Sponsors
collaborator

Biocompatibles UK Ltd

INDUSTRY

lead

Boston Scientific Corporation

INDUSTRY